Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Rheumatology (Oxford, England)|July 30, 2009
Reproducibility of performance measures of physical function based on the BASFI, in ankylosing spondylitisSalima F E van Weely, Christiaan J van Denderen, Irene E van der Horst-Bruinsma, et al.
The Journal of Rheumatology|July 4, 2008
Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritisMike J L Peters, Vokko P van Halm, Michael T Nurmohamed, et al.
The Journal of Rheumatology|February 5, 2005
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritisMarijn Vis, Michael T Nurmohamed, Gertjan Wolbink, et al.
Seminars in Arthritis and Rheumatism|June 14, 2011
The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysisAlper M van Sijl, Mike J L Peters, Dirk L Knol, et al.
Rheumatology (Oxford, England)|July 19, 2013
What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical functionSalima F E van Weely, J Christiaan van Denderen, Martijn P M Steultjens, et al.
EULAR Rheumatology Open|June 29, 2026
Healthcare providers' awareness and knowledge of recommendations on cardiovascular risk management in people with rheumatic and musculoskeletal diseases: a survey studyDina Husum, Julie Katrine Karstensen, Massimo Radin, et al.
Annals of the Rheumatic Diseases|February 28, 2019
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexateLeonieke J J van Mens, Henriëtte M de Jong, Inka Fluri, et al.
Clinical Rheumatology|April 28, 2019
Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practiceVivian P Bykerk, Andrew J K Östör, José Alvaro-Gracia, et al.
Arthritis Research & Therapy|May 1, 2012
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsHennie G Raterman, Saskia Vosslamber, Sander de Ridder, et al.
JAMA|April 14, 2011
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upGeertje M Bartelds, Charlotte L M Krieckaert, Michael T Nurmohamed, et al.
Pageof 18